Tag : SUPER RESPONSE

CONFERENCE UPDATE

Profiling guselkumab super responders in Chinese patients with moderate-to-severe psoriasis: Insights from a phase 4 RCT post-hoc analysis
Guselkumab showed promising results in achieving significant scalp skin clearance among Chinese patients with moderate-to-severe psoriasis, as highlighted in a phase 4 study analysis. In this analysis, super responders (PASI 100) tended to be younger, had lower body weight, and had no prior use of non-biologic systemic therapy.